Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients
- PMID: 16251822
- DOI: 10.1097/01.aids.0000192093.46506.e5
Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients
Abstract
Pharmacotherapy for substance abuse is a rapidly evolving field comprising both old and new effective treatments for substance use. Opiate agonist therapy has been shown to diminish and often eliminate opiate use. This behavior change has resulted in the reduced transmission of many infections, including HIV, hepatitis C virus (HCV), and an enhanced quality of life. For the past 35 years, the provision of opioid agonist therapy has been limited to opioid treatment programmes. Opioid treatment programmes treat approximately 200,000 of the estimated million opiate-addicted individuals in the United States. With the need to increase the number of treatment opportunities available for opioid-dependent patients, Congress passed the Drug Addiction Treatment Act of 2000, which allows for the treatment of opioid dependence using buprenorphine by a properly licensed physician, including HIV primary care physicians. The integration of buprenorphine treatment for opioid addiction into HIV primary care thus provides a new treatment paradigm to address substance abuse in patients with HIV and HCV infections.
Similar articles
-
Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.J Natl Med Assoc. 2012 Jul-Aug;104(7-8):342-50. doi: 10.1016/s0027-9684(15)30175-9. J Natl Med Assoc. 2012. PMID: 23092049 Free PMC article. Review.
-
Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S68-75. doi: 10.1097/QAI.0b013e31820a8226. J Acquir Immune Defic Syndr. 2011. PMID: 21317597
-
Initial strategies for integrating buprenorphine into HIV care settings in the United States.Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S191-6. doi: 10.1086/508183. Clin Infect Dis. 2006. PMID: 17109306 Review.
-
The medical management of opioid dependence in HIV primary care settings.Curr HIV/AIDS Rep. 2006 Nov;3(4):195-204. doi: 10.1007/s11904-006-0016-z. Curr HIV/AIDS Rep. 2006. PMID: 17089480 Review.
-
Models for integrating buprenorphine therapy into the primary HIV care setting.Clin Infect Dis. 2006 Mar 1;42(5):716-21. doi: 10.1086/500200. Epub 2006 Jan 24. Clin Infect Dis. 2006. PMID: 16447120
Cited by
-
Machine learning assisted-nanomedicine using magnetic nanoparticles for central nervous system diseases.Nanoscale Adv. 2023 Jul 28;5(17):4354-4367. doi: 10.1039/d3na00180f. eCollection 2023 Aug 24. Nanoscale Adv. 2023. PMID: 37638161 Free PMC article. Review.
-
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.Curr Vasc Pharmacol. 2016;14(3):280-7. doi: 10.2174/1570161114666160106151652. Curr Vasc Pharmacol. 2016. PMID: 26733388 Free PMC article.
-
Hepatitis infection in the treatment of opioid dependence and abuse.Subst Abuse. 2008 Apr 28;1:15-61. doi: 10.4137/sart.s580. eCollection 2008. Subst Abuse. 2008. PMID: 25977607 Free PMC article. Review.
-
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb. Ther Drug Monit. 2011. PMID: 21544014 Free PMC article. Clinical Trial.
-
Limited uptake of hepatitis C treatment among injection drug users.J Community Health. 2008 Jun;33(3):126-33. doi: 10.1007/s10900-007-9083-3. J Community Health. 2008. PMID: 18165889 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
